SURVYR

IAM New listing

Iambic Therapeutics, Inc.
IPO · listed Oct 15, 2026
$13.79
−$0.88 (6.00%)Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-31%-15%+1%+16%+32%Oct 15Oct 23Oct 1952w high $25.0052w low $13.02
IAMSPY
Wall St. Highest PT $30.21 (+119.1%) Wall St. Avg PT $24.76 (+79.6%)
$14$21$27$34$41POC $16Hi $30Avg $25
Underwater Drawdown %Max DD -42.1%Current -42.1%
0.0%-42.1%
Relative Strength vs SPY-25.5% vs SPYUnderperforming
+31%0%-31%
1W
−$10.02 (42.08%)
1M
–
3M
–
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street & Morningstar coverage
Wall Street consensusNo covering analysts on file for IAM
Analyst price targetsNo target range on file
Morningstar star ratingNot rated
Checked Wall Street & Morningstar feeds · All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$675.9M
52-week range$13.02 – $25.00
Revenue growth (latest quarter vs a year ago)+224.7%
Dividend yieldNo dividend

What they do

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor. Iambic Therapeutics, Inc. was formerly known as Entos.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for IAM yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

IAM earningsNo upcoming date on file
Source: Yahoo Finance · refreshed 2026-10-24 02:46:22 ET
No EPS history available.

News & catalysts

More news
Iambic Therapeutics (IAM) Filed An IND For IAM217
Simply Wall St. · Oct 18
Iambic Therapeutics (IAM) Joins The Nasdaq Composite, Is The Stock Already Pricey?
Simply Wall St. · Oct 17
Another Biotech IPO Pops on Rough Day for Broader Market
Barrons.com · Oct 16
Cathie Wood-Backed Biotech IPO Pops in Debut
Barrons.com · Oct 15
GTT Group Founder Michael Lubitz Joining Expert Panel at IAM Patent Transactions 2026 in San Diego
PR Newswire · Oct 15

Stats refreshed 2026-10-24 02:46:22 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026